In fact, glucosamine improved colitis symptoms in DSS-treated mice by preventing intestinal epithelial cell activation and tight junction proteins expression decrease, with a parallel decrease in the nuclear factor-kappa B (NF-kB) activity and reduced TNF-α and IL-1β release [11,12]. The gene discussed is IL1B; the disease is colitis.